摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-chloro-2-isopropoxy-propan-1-ol | 78925-49-2

中文名称
——
中文别名
——
英文名称
3-chloro-2-isopropoxy-propan-1-ol
英文别名
3-Chlor-2-isopropoxy-propan-1-ol;3-Chlor-2-isopropoxy-1-propanol;3-Chloro-2-propan-2-yloxypropan-1-ol
3-chloro-2-isopropoxy-propan-1-ol化学式
CAS
78925-49-2
化学式
C6H13ClO2
mdl
MFCD19232902
分子量
152.621
InChiKey
JDLYRVRYZHZYAK-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    225.3±20.0 °C(Predicted)
  • 密度:
    1.062±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.9
  • 重原子数:
    9
  • 可旋转键数:
    4
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    29.5
  • 氢给体数:
    1
  • 氢受体数:
    2

反应信息

  • 作为产物:
    描述:
    4-(氯甲基)-2,2-二甲基-1,3-二噁烷 在 lithium aluminium tetrahydride 、 三氯化铝 作用下, 生成 3-chloro-2-isopropoxy-propan-1-ol
    参考文献:
    名称:
    取代基对取代 1,3-二氧杂环戊烷在 LiAlH4-AlCl3 还原裂解过程中开环的容易程度和方向的影响
    摘要:
    研究了 LiAlH4–AlCl3 在室温下氢解许多 1,3-二氧戊环的醚溶液。环的 C2 原子上的电子给体取代基加速,同时电...
    DOI:
    10.1139/v64-154
点击查看最新优质反应信息

文献信息

  • Opening of cyclic acetals by trichloro-, dichloro-, and tribromo-borane
    作者:Trevor G. Bonner、David Lewis、Keith Rutter
    DOI:10.1039/p19810001807
    日期:——
    The rate-determining step in the ring opening of cyclic acetals by trichloroborane to yield α-chloro-ethers is shown to be consistent with the formation of an oxocarbenium ion. Subsequent reduction provides a general route for the conversion of a diol into a hydroxy-ether. Tribromoborane is a more powerful and dichloroborane a less powerful reagent than trichloroborane.
    通过三氯硼烷在环缩醛的开环反应中生成α-氯醚的速率确定步骤表明与氧碳鎓离子的形成是一致的。随后的还原提供了二醇转化为羟基醚的一般途径。与三氯硼烷相比,三溴硼烷是一种更强大的试剂,而二氯硼烷是一种性能较差的试剂。
  • Protein tyrosine phosphatase inhibitors and methods of use thereof
    申请人:Calico Life Sciences LLC
    公开号:US10954202B2
    公开(公告)日:2021-03-23
    Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases, disorders and conditions favorably responsive to PTPN1 or PTPN2 inhibitor treatment, e.g., a cancer or a metabolic disease.
    本文提供的化合物、组合物和方法可用于抑制蛋白酪氨酸磷酸酶,例如蛋白酪氨酸磷酸酶非受体2型(PTPN2)和/或蛋白酪氨酸磷酸酶非受体1型(PTPN1),以及治疗对PTPN1或PTPN2抑制剂治疗有良好反应的相关疾病、失调和病症,例如癌症或代谢性疾病。
  • Investigation of the catalytic activity of an electron-deficient vanadium(IV) tetraphenylporphyrin: A new, highly efficient and reusable catalyst for ring-opening of epoxides
    作者:S. Abdolmanaf Taghavi、Majid Moghadam、Iraj Mohammadpoor-Baltork、Shahram Tangestaninejad、Valiollah Mirkhani、Ahmad Reza Khosropour、Venus Ahmadi
    DOI:10.1016/j.poly.2011.06.008
    日期:2011.8
    In this work, the catalytic activity of high-valent tetraphenylporphyrinatovanadium(IV) trifluoromethanesulfonate, [V-IV(TPP)(OTf)(2)], in the nucleophilic ring-opening of epoxides is reported. This new V(IV) catalyst was used as an efficient catalyst for alcoholysis with primary (methanol, ethanol and n-propanol), secondary (iso-propanol) and tertiary alcohols (tert-butanol), hydrolysis and acetolysis of epoxides with acetic acid and also for the conversion of epoxides to 1,2-diacetates with acetic anhydride, conversion of epoxides to thiiranes with ammonium thiocyanate and thiourea, and for conversion of epoxides to acetonides with acetone. The catalyst was reused several times without loss of its activity. (C) 2011 Elsevier Ltd. All rights reserved.
  • BONNER T. G.; LEWIS D.; RUTTER K., J. CHEM. SOC. PERKIN TRANS., 1981, PART 1, NO 7, 1807-1810
    作者:BONNER T. G.、 LEWIS D.、 RUTTER K.
    DOI:——
    日期:——
  • PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF
    申请人:Calico Life Sciences LLC
    公开号:US20210009542A1
    公开(公告)日:2021-01-14
    Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases, disorders and conditions favorably responsive to PTPN1 or PTPN2 inhibitor treatment, e.g., a cancer or a metabolic disease.
查看更多